Learn about Plant-based Biopharmaceuticals

Biopharmaceuticals are at the vanguard of the pharmaceutical industry, creating medicines from nature. Using plants, both cannabinoids or others, we are creating products to treat diseases which cause suffering to millions across the globe.

Understanding Plant-based Medicine

Through the use of natural elements and science, we are able to provide patients with cutting edge pharmaceuticals to treat disease processes, symptoms and improve overall wellbeing. This is made possible through our understanding of plants and their intrinsic medicinal qualities.

Understanding Cannabinoids and their usage

Our experienced research team has a strong understanding of Cannabinoids, based on extensive clinical and pharmacological experience, combined with the scientific knowledge of our team and collaborators across academic institutions globally.

Plant-based medicines to treat

Epilepsy

Epilepsy

CBD-THC products have been shown to be safe and efficacious in real world settings when used to control seizures that could not be effectively managed by standard medical treatments.

Dementia

Dementia

Phytocannabinoid derived IMP’s are currently in clinical development for the management of BPSD (Behavioural and Psychological Symptoms in Dementia) based on real world data which supports the potential for this implementation.

COVID-19

COVID-19

Natural based ingredients such as Curcumin, Boswellia serrata, Artemisinin and Vitamin C, have demonstrated their effectiveness during Stage II clinical trials and serve to modulate inflammatory / immune markers associated with the COVID-19 virus.

Cancer

Cancer

Clinical experience supports the use of various cannabinoid-based formulations for the amelioration of a range of diseases and the treatment of related symptoms. These include various types of pain, pruritus (itching), sleep disorders, poor appetite, anxiety and more.

Crohn's Disease

Crohn's Disease

Cannabinoids, such as those made available in MGC products, have been used both historically and in recent times, with particular success in Crohn’s disease for the management of symptoms such as pain, loss of appetite, and diarrhoea.

Cerebral Palsy

Cerebral Palsy

Clinical experience corroborates the evidence-based use of cannabinoids for the management of seizures and spasticity, both of which have a substantial impact on the lives of those affected by cerebral palsy as well as their caretakers and families.

CBD-THC products have been shown to be safe and efficacious in real world settings when used to control seizures that could not be effectively managed by standard medical treatments.
Phytocannabinoid derived IMP’s are currently in clinical development for the management of BPSD (Behavioural and Psychological Symptoms in Dementia) based on real world data which supports the potential for this implementation.
Natural based ingredients such as Curcumin, Boswellia serrata, Artemisinin and Vitamin C, have demonstrated their effectiveness during Stage II clinical trials and serve to modulate inflammatory / immune markers associated with the COVID-19 virus.
Clinical experience supports the use of various cannabinoid-based formulations for the amelioration of a range of diseases and the treatment of related symptoms. These include various types of pain, pruritus (itching), sleep disorders, poor appetite, anxiety and more.
Cannabinoids, such as those made available in MGC products, have been used both historically and in recent times, with particular success in Crohn’s disease for the management of symptoms such as pain, loss of appetite, and diarrhoea.
Clinical experience corroborates the evidence-based use of cannabinoids for the management of seizures and spasticity, both of which have a substantial impact on the lives of those affected by cerebral palsy as well as their caretakers and families.

Developing treatments based on natural, plant derived ingredients

Once brought to the level of API (Active Pharmaceutical Ingredient) through a careful and regulated process of isolation and purification, using our GMP state-of-art research and production facilities, we are able to create the ratios and formulations to treat symptoms and diseases. These APIs are the building blocks of our medicines which possess proven biological activity and great potential for successful formulation into more effective treatments for patients the world over

Plant-based Medicine versus Standard Pharmaceuticals

Have the advantage of safe and effective use by humanity over millennia. This narrows the challenge of drug development to the characterisation and refinement of the desired pharmacological features in suitable formulations, with higher probability of success as compared to other drug discovery approaches.

Leading the global shift towards plant-based, naturally harmonious medicines, improving lives and public health.

Rob Clements

Chief Commercial Officer

After starting his career with an initial spell in the City of London Rob joined the pharmaceutical industry in 1991. Over the following decade he progressed rapidly through field roles to Marketing Management. He then established his own consultancy specialising in relationship marketing and product launch for healthcare companies.

He subsequently worked in business development roles identifying potential product acquisitions – both prescription and OTC – the development and launch of medical devices and general strategic functions. His roles included improving business performance and company morale, and oversight of companies’ core marketing of ethical brands.

From 2011 Rob headed a pan-national team for Forest Laboratories delivering new ethical products to markets alongside management of the existing portfolio. As Director both of Marketing and Commercial operations he was also directly responsible for budgeting, planning and data provision, whilst remaining closely involved with the assessment of BD opportunities.

An expert in specialist disease marketing and business development Rob has also worked extensively on a number of proposed private equity asset buyouts in addition to previous consultancy work.

From 2019 he worked with Healthcare at Home (now Sciensus Rare) to help establish an international rare medicines division. As Vice President of Business Development his role included ongoing development and refinement of the service offering and building new business opportunities; from strategic partnerships and potential MA acquisitions through to establishing Sciensus Rare’s global footprint.